COMP <GO>
KYMR vs IBRX // ENTERPRISE SCALE & MARKET CAP
Kymera Therapeutics Inc. (NASDAQ) VS. ImmunityBio Inc. (NASDAQ) • 15-METRIC TALLY: KYMR 6
— IBRX 4
▲ ENTERPRISE SCALE & MARKET CAP LEADER: KYMR
LAST: $126.63 (+3.29%) • MKT CAP: $10.81B
market-cap
$10.81B
LAST: $8.29 (-5.15%) • MKT CAP: $8.79B
market-cap
$8.79B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYMR VS. IBRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KYMR | IBRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.40% | -27.30% | +5.90 | KYMR | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.30% | -3.33% | +1.03 | KYMR | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | 68.00% | -60.00% | +128.00 | KYMR | /net-margins <GO> |
| Revenue Growth (YoY) | -16.70% | 180.00% | -196.70 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 0.45 | +25.55 | KYMR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 6/9 | -2.00 | IBRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.0 | 44.3 | +21.70 | KYMR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.05 | -0.10 | IBRX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.4x | 29.0x | +1.40 | IBRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $10.81B | $8.79B | $2.02B | KYMR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KYMR REV | IBRX REV | KYMR GROSS % | IBRX GROSS % | KYMR FCF | IBRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $39.2M | $113.3M | 0.0% | 99.3% | -$234.3M | -$308.8M |
| FY 2024 | $47.1M | $14.7M | 0.0% | 100.0% | -$207.3M | -$398.1M |
| FY 2023 | $78.6M | $622.0K | — | — | -$106.4M | -$366.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYMR // BETA 0.95
IBRX // BETA 1.05